Insider Selling: Voyager Therapeutics (NASDAQ:VYGR) COO Sells 6,458 Shares of Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 6,458 shares of Voyager Therapeutics stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $3.77, for a total value of $24,346.66. Following the completion of the sale, the chief operating officer directly owned 199,738 shares of the company’s stock, valued at $753,012.26. This trade represents a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Robin Swartz also recently made the following trade(s):

• On Tuesday, February 10th, Robin Swartz sold 4,569 shares of Voyager Therapeutics stock. The shares were sold at an average price of $3.85, for a total value of $17,590.65.

Voyager Therapeutics Trading Up 1.0%

Voyager Therapeutics stock traded up $0.04 during mid-day trading on Thursday, hitting $4.13. The stock had a trading volume of 151,278 shares, compared to its average volume of 584,842. The stock has a 50-day simple moving average of $3.86 and a two-hundred day simple moving average of $4.11. The stock has a market capitalization of $229.63 million, a PE ratio of -1.91 and a beta of 1.30. Voyager Therapeutics, Inc. has a 12 month low of $2.64 and a 12 month high of $5.55.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of VYGR. Bank of Montreal Can acquired a new stake in shares of Voyager Therapeutics in the second quarter valued at approximately $36,000. Wexford Capital LP bought a new stake in shares of Voyager Therapeutics during the third quarter worth approximately $42,000. ProShare Advisors LLC bought a new position in shares of Voyager Therapeutics during the fourth quarter worth approximately $44,000. CIBC Asset Management Inc acquired a new position in Voyager Therapeutics in the 4th quarter valued at $45,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Voyager Therapeutics in the second quarter valued at about $50,000. Institutional investors own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on VYGR shares. HC Wainwright reduced their price objective on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, November 12th. Wall Street Zen downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Finally, Wedbush restated an “outperform” rating and set a $8.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Voyager Therapeutics has an average rating of “Moderate Buy” and an average price target of $13.75.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.